Emjard 10
- Emjard, an SGLT-2 inhibitor, empowers glycemic control and reduces cardiovascular risks in adults with type 2 diabetes mellitus.
- Its mechanism involves inhibiting renal glucose reabsorption, resulting in enhanced glucose excretion.
- Administered once daily, Emjard offers convenience and efficacy in managing diabetes.
- Caution is advised in patients with renal impairment, and regular monitoring ensures optimal therapeutic outcomes.
Emjard 25
- Emjard is a medication for adults with type 2 diabetes mellitus.
- It improves glycemic control when combined with diet and exercise.
- By inhibiting sodium glucose co-transporter-2 (SGLT-2) in the kidneys:
- Increases glucose excretion
- Promotes weight loss
- Reduces blood pressure
- Emjard is available in tablet form for once-daily administration, with or without food.
- Patients should follow recommended dosages and consult healthcare professionals for optimal diabetes management.